Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.67 USD
0.00 (-0.30%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.67 0.00 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
GOSS 0.67 0.00(-0.30%)
Will GOSS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GOSS
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
Other News for GOSS
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
Gossamer Bio assumed with an Outperform at Wedbush
Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape